Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry
Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry
复制标题
DOI：
10.1136/rmdopen-2018-000880
复制
发表时间：
2019-02-01
期刊：
影响因子：
6.2
通讯作者：
Greenberg, Jeffrey D.
中科院分区：
文献类型：
--
作者：
Mease, Philip J.;Karki, Chitra;Greenberg, Jeffrey D.
目的研究美国银屑病关节炎（PsA）患者中肿瘤坏死因子抑制剂（TNFi）的使用模式。方法纳入所有年龄≥ 18岁的PsA患者，这些患者在2013年3月至2017年1月期间开始TNFi（指标治疗），并进行了≥ 1次随访。在TNFi初治和TNFi经历队列之间比较了指数TNFi的停药/转换的时间和比率。在TNFi启动（基线）时，患者的人口统计学和疾病特征进行了比较，队列之间和患者之间谁继续与停止其指数TNFi的第一次随访visit在每个cohol.Results本研究包括171 TNFi-幼稚和147 TNFi经验丰富的患者（总随访，579.2人年）。总体而言，171例TNFi初治患者中的75例（43.9%）和147例TNFi经验患者中的80例（54.4%）停止了他们的指标TNFi; 171例患者中的33例（19.3%）和147例患者中的48例（32.7%）分别改用新的生物制剂。TNFi治疗患者的停药时间较短（中位数，20 vs 27个月），更可能停药（p=0.03）或转换（p
Objective To examine patterns of tumour necrosis factor inhibitor (TNFi) use in TNFi-naive and TNFi-experienced patients with psoriatic arthritis (PsA) in the USA.Methods All patients aged >= 18 years with PsA enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry who initiated a TNFi (index therapy) between March 2013 and January 2017 and had >= 1 follow-up visit were included. Times to and rates of discontinuation/switch of the index TNFi were compared between TNFi-naive and TNFi-experienced cohorts. Patient demographics and disease characteristics at the time of TNFi initiation (baseline) were compared between cohorts and between patients who continued versus discontinued their index TNFi by the first follow-up visit within each cohort.Results This study included 171 TNFi-naive and 147 TNFi-experienced patients (total follow-up, 579.2 person-years). Overall, 75 of 171 TNFi-naive (43.9%) and 80 of 147 TNFi-experienced (54.4%) patients discontinued their index TNFi; 33 of 171 (19.3%) and 48 of 147 (32.7%), respectively, switched to a new biologic. TNFi-experienced patients had a shorter time to discontinuation (median, 20 vs 27 months) and were more likely to discontinue (p=0.03) or switch (p